Study drug RMC-9805 for patients with KRAS G12D solid tumors (RMC-9805-001)

What is the Purpose of this Study?

We are doing this study to find out if an investigational drug called RMC-9805 (the study drug) is a safe and effective option for treating KRAS G12D mutated cancer. We are also trying to figure out what dose of the study drug works best for most people.

What is the Condition Being Studied?

Solid Tumors With KRAS G12D Mutation

Who Can Participate in the Study?

Adults ages 18+ who:

  • Have solid tumor(s) that are locally advanced or metastatic
  • Have a documented KRAS G12D mutation
  • Have worsened following standard therapy

For more information about who can join this study, contact the study team at 919-668-1861.

Age Group

What is Involved?

If you choose to join this study, you will:

  • Take the study drug by mouth every day
  • Have your tumor biopsied
  • Give blood and urine samples
  • Have regular CT or MRI scans

Study Details

Full Title
[RMC-9805-001] Phase 1/1b, multicenter, open-label, study of RMC-9805 in participants with advanced KRASG12D-mutant solid tumors
Principal Investigator
Professor of Medicine
Protocol Number
IRB: PRO00114818
NCT: NCT06040541
Phase I
Enrollment Status